Prolactin

Prolactin (PRL) is a 23-kDa protein hormone primarily produced by lactotroph cells in the anterior pituitary gland, with additional synthesis occurring in various peripheral tissues. Researchers primarily study prolactin for its critical roles in reproductive functions, maternal behavior, and its involvement in various physiological and pathophysiological processes. Key findings indicate that PRL signaling is mediated through its unique receptor (PRLR) and the JAK2/Stat5 pathway, while recent studies have highlighted its implications in conditions such as migraines, metabolic disorders, and certain cancers. Current research continues to explore the diverse functions of prolactin, including its autocrine and paracrine activities, as well as the potential therapeutic applications of prolactin receptor antagonists. Clinical evidence indicates that understanding prolactin's multifaceted roles may lead to novel insights into both normal physiology and disease mechanisms.

Prolactin (PRL), also known as Luteotropin or Luteotropic Hormone, is an endogenous hormone primarily synthesized and secreted by lactotroph cells in the anterior pituitary gland, though it is also produced in smaller quantities by various peripheral tissues. It belongs to the category of pituitary and trophic hormones. PRL is a 23-kDa protein that plays a significant role in numerous physiological processes. Researchers have observed that prolactin is crucial for reproductive functions, including lactation and maternal behavior. Beyond its reproductive roles, prolactin is involved in metabolic homeostasis, immune regulation, and has been implicated in conditions such as migraines, cancer, and autoimmune diseases. The primary mechanism of prolactin action involves binding to the prolactin receptor (PRLR), a transmembrane receptor. This interaction predominantly activates the JAK2/Stat5 signaling pathway, which is essential for mediating its biological effects. Additionally, prolactin can be cleaved into a shorter form, vasoinhibin, whose signaling pathways are not fully understood. Pharmacokinetic data on prolactin, particularly its half-life and metabolism, are limited. However, it is known that prolactin is subject to pulsatile secretion and its levels can vary based on the time of day. Clinically, prolactin has been explored for its potential therapeutic applications, particularly in the context of breast cancer, where PRL receptor antagonists are being investigated. Its regulatory status varies by country, and it is typically not used as a direct therapeutic agent but rather studied for its physiological and pathological roles.

Prolactin acts primarily through the prolactin receptor (PRLR), which is a transmembrane receptor. Upon binding, it activates the JAK2/Stat5 signaling pathway, leading to a cascade of biological effects that include modulation of reproductive and immune functions.

Prolactin (PRL) primarily exerts its effects through binding to the prolactin receptor (PRLR), activating the JAK2/STAT5 signaling pathway, which is crucial for mediating its biological functions. This signaling cascade influences various processes, including reproductive functions, maternal behavior, and metabolic homeostasis, while also playing roles in inflammation, autoimmune diseases, and cancer. Although the canonical pathway is well characterized, the complete mechanisms of action, particularly for the cleaved form of PRL (vasoinhibin) and its signaling, remain not fully understood.

Current evidence is limited regarding the specific signaling mechanisms of the cleaved 16-kDa prolactin (vasoinhibin) and its distinct physiological roles, necessitating further research to elucidate its functions and potential therapeutic applications. Additionally, the impact of prolactin receptor (PRLR) polymorphisms on disease susceptibility, particularly in breast and prostate cancers, remains poorly understood, highlighting the need for larger cohort studies and genetic analyses in diverse populations. Furthermore, the development and efficacy of prolactin receptor antagonists in modulating autocrine and paracrine signaling in various tissues require more extensive preclinical and clinical trials to establish their therapeutic potential.